Biodegradable Synthetic Scaffold as a Substitute for hAM in Limbal Epithelial Cells Transplant in LSCD Patients

Limbal Stem Cell Deficiency Clinical Trial

Official title:

Study to Evaluate Safety & Efficacy of PLGA Scaffold to Regenerate Limbal Epithelial Cells Using Autologous Limbal Grafts by SLET (Simple Limbal Epithelial Transplant) Procedure in Patients Having Total Unilateral LSCD

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02568527
• Other study ID #: LVPEI-2012-11
• Status: Completed
• Phase: N/A
• Start date: October 2015
• Est. completion date: July 2018

Study information

• Verified date: April 2016
• Source: L.V. Prasad Eye Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this clinical study is to undertake a pilot safety and efficacy study of a synthetic biodegradable membrane as a substitute for using donor human amniotic membrane (hAM) for the treatment of limbal stem cell deficiency (LSCD) by combining this with freshly excised limbal tissue in theatre as a one stage procedure

Description:

This study will involve the used of a synthetic biodegradable Poly Lactide-co-Glycolic Acid (PLGA) biodegradable, synthetic carrier membrane (PLGA) membrane as a substitute for using donor human amniotic membrane (hAM) for the treatment of limbal stem cell deficiency (LSCD) by combining this with freshly excised limbal tissue in theatre as a one stage procedure.

This has the potential to simplify the current procedure and make it safer and accessible to more surgeons and eventually benefit more patients. The use of PLGA membrane, in place of hAM for limbal transplants, is a novel technique and has a lot of promise and potential, which will potentially benefit patients at large and significantly bring down costs for the limbal transplants while reducing the disease transmission risks of using human donor tissue.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5
• Est. completion date: July 2018
• Est. primary completion date: October 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Male and female participants who are =18 years of age.

2. Patients having a confirmed diagnosis of total LSCD as confirmed by any one or all of the following:

• In-growth of conjunctival epithelium over the cornea (conjunctivalization),

• 360o absence of limbal Palisades of Vogt,

• A fine stippled appearance on fluorescein staining,

• Persistent or recurrent corneal epithelial defects

• Superficial vascularization,

• Dull and irregular corneal epithelium.

3. Participants having unilateral limbal stem cell deficiency due to chemical injury

4. No prior history of limbal transplantation

5. No ongoing and other active ocular pathology

6. No severe pathological and psychological conditions that might interfere with the patients participation in the study

7. Able to provide written informed consent prior to any study specific screening procedures with the understanding that the patient has the right to withdraw from the study at any time, for any reason without prejudice.

Exclusion Criteria:

1. Bilateral LSCD

2. LSCD due to autoimmune disorders and partial LSCD

3. Having other ongoing ocular pathologies and acute ocular inflammation

4. Previous neoplastic/cancer disease

5. Severe dry eyes confirmed by Schirmer's test

6. Acute systemic infections

7. Prior history of limbal transplantation surgery or multiple surgeries in the limbal region

8. Substance abuse, medical, psychological or social conditions that may, in the opinion of the investigator, interfere with the patient's participation in the study or evaluation of the study results.

9. Any uncontrolled, inter-current illness that in the opinion of the Investigator may interfere with study evaluation.

10. Participants with uncontrolled diabetes will be excluded from the study

11. History or evidence of cardiac disease: congestive heart failure; New York Heart Association (NYHA) class 2 or greater (see Appendix 6); active coronary artery disease; unstable angina, cardiac arrhythmias requiring anti-arrhythmic therapy, atrio-ventricular block of second or third degree, or uncontrolled hypertension, patients with recent (less than 6 months) myocardial infarction (MI) or coronary revascularization.

12. Pregnant and lactating patients, positive urine pregnancy test in women of childbearing potential

13. Reproductive age patients not practicing effective and adequate birth control measures

14. Participation in any other investigational trial in which receipt of investigational drug or device occurred within 30 days prior to screening for this study.

15. Previous participation in this study

Related Conditions & MeSH terms

• Limbal Stem Cell Deficiency

Intervention

Device:
• PLGA scaffold
Poly-Lactic-co-Glycolic Acid (50:50) biodegradable, synthetic scaffold

Locations

Country	Name	City	State
India	LV Prasad Eye Institute	Hyderabad	Andhra Pradesh

Sponsors (3)

Lead Sponsor	Collaborator
Virender S Sangwan, MBBS, MS	University of Sheffield, Wellcome Trust

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Corneal Edema using Pachymetry	At Baseline and at Month 12	12 months
Primary	Intraocular Pressure by Standard Applanation Tonometry	At Baseline and at Month 12	12 months
Primary	Ocular Pain	Magnitude of pain will assessed as patient reported outcome using Visual Analogue Scale (VAS) in a scale of 1 to 10 (Wong-Baker Faces Pain Rating Scale)	12 months
Primary	Schirmer's test (5 minute) without anesthesia		12 months
Primary	Clinical Laboratory Adverse Events		12 months
Primary	Vital Signs		12 months
Secondary	Regeneration of Stable Ocular Surface measured by Slit lamp Biomicroscopy Examination and Slit Lamp Photography		12 months
Secondary	Best Corrected Visual Acuity by Snellen Chart		12 months